FabRx
FabRx is a UK-based pharmaceutical technology company that develops GMP-compliant M3DIMAKER 3D printing systems and supporting software for personalized medicine production, serving hospital pharmacies, community pharmacies, pharmaceutical companies, and academic research institutions worldwide.
- Company typePrivate
- Founded2014
- HeadquartersAshford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What FabRx does
FabRx is a UK-based pharmaceutical technology company that develops and commercializes the M3DIMAKER ecosystem for the on-site production of personalized medicines. Its hardware platform comprises the GMP-compliant M3DIMAKER 1 (single printhead) and M3DIMAKER 2 (multi-printhead) pharmaceutical 3D printers, supported by exchangeable printheads spanning Semi-Solid Extrusion (SSE), Fused Deposition Modelling (FDM), and Direct Powder Extrusion (DPE), as well as integrated quality-control accessories including a Near-Infrared sensor, pressure sensor, in-built balance, and traceability system. The company extends the platform beyond 3D printing into blister, capsule, and suppositories filling technologies, offering an end-to-end compounding automation stack for hospital and community pharmacies.
The business operates a hybrid revenue model combining hardware sales (M3DIMAKER 2 and enterprise solutions), recurring subscriptions for M3DIMAKER 1 (from €1999/month targeted at European pharmacies and hospitals), software licensing for M3DIMAKER Studio and the Hub & Spoke compliance tier, and professional services through its Pharma-ink formulation development offering. Go-to-market is executed via direct enterprise sales to pharmaceutical companies, CDMOs, and large research institutions, a direct European website channel for pharmacy and hospital customers, and a 2025 strategic channel partnership with Pete Pharma for U.S. compounding pharmacies. Software and AI capabilities are housed in a wholly-owned Spanish subsidiary, FABRX·AI (launched 2023), which builds M3DIMAKER Studio, M3DIFEEDBACK, and the M3DISEEN printability-prediction tool.
FabRx's customer base spans pharmaceutical companies (Pfizer, AstraZeneca), leading pediatric and oncology hospitals (Great Ormond Street Hospital, Gustave Roussy, Vall d'Hebron University Hospital, Erasmus MC, Hospital General Universitario Dr. Balmis), academic research institutions (UCL, Cambridge, Monash, Maryland, Montreal, Heidelberg), and government agencies including the U.S. Centers for Disease Control and Prevention and Fiocruz. The company is founder-owned with no disclosed institutional funding, operates subsidiaries in the UK (London HQ), Spain (Madrid), and the United States, and was recognized with the King's Award for Enterprise 2026 in Innovation.
FabRx firmographics
Firmographics- Name
- FabRx
- Legal name
- FABRX Ltd.
- Website
- https://fabrx.co.uk
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FabRx is a UK-based pharmaceutical technology company that develops GMP-compliant M3DIMAKER 3D printing systems and supporting software for personalized medicine production, serving hospital pharmacies, community pharmacies, pharmaceutical companies, and academic research institutions worldwide.
- Ownership category
- akta.pro rank
FabRx industry classification
Industry- Product category
- Pharmaceutical 3D Printing Systems
- NAICS
- Printing and Related Support Activities (3231), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Printing Trades Machinery & Equipment (3555), Industrial Instruments For Measurement, Display, And Control (3823)
- akta.pro primary industry
- Compounding Pharmacy & Sterile Prep Workflow Systems (HLACAKAM)
- akta.pro secondary industries
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Machine Control, Firmware & Print Management (IMAAACAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where FabRx is headquartered
LocationHeadquarters
- HQ city
- Ashford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
FabRx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical 3D Printer Sales: Sale of M3DIMAKER 1 and M3DIMAKER 2 pharmaceutical 3D printers to pharmacies, hospitals, and research institutions. Printers are GMP compliant and designed for personalized medicine production.
- Printer Subscription: Monthly subscription model for M3DIMAKER 1 starting from €1999 per month, specifically targeting pharmacies and hospitals in Europe.
- Software Licensing: M3DIMAKER Studio software licensing with two tiers: Studio for basic printer control and Pharma-ink management, and Hub & Spoke for enhanced regulatory compliance with secure VPN access and performance reports.
- Pharma-ink Development Services: Flexible formulation development services from consultation to full formulation development and analysis, helping develop and optimise 3D printable formulations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | M3DIMAKER 1 - Single printhead pharmaceutical 3D printer subscription |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
FabRx product offering
Product offeringCore offering
FabRx develops and commercializes the M3DIMAKER ecosystem of GMP-compliant pharmaceutical 3D printers (single-printhead M3DIMAKER 1 and multi-printhead M3DIMAKER 2), control software, in-line quality control sensors, and Pharma-ink formulation services that enable pharmacies, hospitals, and pharmaceutical companies to produce personalized medicines and small-batch pharmaceuticals on-site. The platform supports multiple manufacturing modalities including 3D printing, blister filling, capsule filling, and suppository filling under a single integrated system.
Product overview
FabRx is a pharmaceutical technology company offering the M3DIMAKER ecosystem, a unified platform comprising hardware (M3DIMAKER 1 and M3DIMAKER 2 pharmaceutical 3D printers), software (M3DIMAKER Studio and Hub & Spoke), and quality control accessories (Near Infrared Sensor, Pressure Sensor, Balance, Traceability). The company provides four distinct manufacturing technologies under one ecosystem: 3D Printing, Blister Filling, Capsule Filling, and Suppositories Filling. Supporting services include Pharma-ink Development for formulation optimization, AI-powered tools (M3DISEEN for printability prediction, M3DIFEEDBACK for patient feedback), and exchangeable printhead systems (SSE, FDM, DPE) for the M3DIMAKER 2. All products are GMP compliant and designed for personalized medicine production in pharmacies, hospitals, and clinical trial settings.
Differentiator
Problem solved
Functional benefit
Brands
- M3DIMAKER: Pharmaceutical 3D printing ecosystem for personalized medicine production including M3DIMAKER 1 (single printhead) and M3DIMAKER 2 (multi-printhead) systems.
- M3DIMAKER Studio
- M3DIFEEDBACK
- M3DISEEN
- Pharma-ink
Products and services
- M3DIMAKER 1 Single printhead, GMP-compliant pharmaceutical 3D printer for research and small-batch manufacture of personalized medicines and medical devices for human and veterinary precision medicine and drug development. Available by monthly subscription (from €1,999/month) targeting European pharmacies and hospitals.
- M3DIMAKER 2 Multi-printhead (3 printhead attachments) GMP-compliant pharmaceutical 3D printer capable of rapid polypill manufacture and higher-throughput, larger batch production of personalized medicines and medical devices. Targeted at pharmaceutical companies, CDMOs, and large research institutions.
- M3DIMAKER Studio Software Bespoke software developed by FABRX·AI that controls the M3DIMAKER ecosystem, enabling 3D model selection, parameter preparation, and printer control. Includes dose-library generator and user group management; protocols can be locked for quality assurance in clinical use, and Hub & Spoke capabilities add secure VPN access, protocol sharing, downloadable libraries, and performance reports.
- M3DISEEN AI-driven predicting tool that assesses 3D printability of pharmaceutical formulations. Takes drug, excipients, and proportions as input, predicts formulation printability, and provides recommended 3D printing parameters and dissolution insights. Currently focused on FDM and offered as an online tool.
- M3DIFEEDBACK Phone application designed to collect patient and carer feedback for clinical projects. Custom downloadable apps can be created for each clinical project to provide a user-friendly feedback experience.
- Pharma-ink Development Services Professional formulation development services ranging from consultation to full formulation development and analysis, including active ingredient characterization, 3D printing optimization, in vitro analysis, and small batch manufacture with clinical trial guidance. Helps customers develop and optimize 3D-printable pharmaceutical formulations.
- FABRX Syringe Preheater Hardware accessory introduced in January 2026 for the M3DIMAKER ecosystem, designed to revolutionize high-volume 3D printing applications by preheating syringes used in pharmaceutical 3D printing.
Quantifiable outcome
- Auto-filling 10,000 capsules with personalized doses in one day
Companies that use FabRx
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles4 records
FabRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature14 records
FabRx partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Pete PharmacoreStrategic partnership to introduce pharmaceutical 3D printing technology to the U.S. compounding pharmacy market. Pete Pharma developed a pharmacy-first business model to reduce operational burden and improve workflow efficiency for independent pharmacies. The partnership combines Pete Pharma's market expertise with FabRx's M3DIMAKER technology (M3DIMAKER 1 for research and small-batch manufacturing, M3DIMAKER 2 for higher throughput) to modernize personalized medicine production through automation and enhanced customization capabilities.
- University College London (UCL)coreFounding research institution and origin of FabRx technology. Co-founders Prof. Alvaro Goyanes and colleagues developed pharmaceutical 3D printing technology at UCL. Ongoing collaboration for research and development of personalized medicine solutions.
- FABRX·AIcoreSubsidiary company launched in 2023 in Spain, focused on advanced software solutions for pharmaceutical 3D printing and automated drug dispensing. Develops M3DIMAKER Studio software, M3DIFEEDBACK app, and M3DISEEN AI prediction tool.
- PfizerminorPharmaceutical company collaboration for personalized medicine development research.
- AstraZenecaminorPharmaceutical company collaboration for personalized medicine research.
- Vall d'Hebron University HospitalminorClinical collaboration for pharmaceutical 3D printing applications in hospital pharmacy settings, including pediatric formulations.
- Great Ormond Street HospitalminorPediatric healthcare institution collaboration for child-friendly personalized medicines using 3D printing technology.
- Gustave RoussyminorCancer research center collaboration for pharmaceutical 3D printing applications in oncology treatments.
Scale indicators2 records
Recent moves8 records
Expansion highlights6 records
FabRx competitors and assessment
Company assessmentDirect peers
- Triastek: Triastek is a Chinese pharmaceutical 3D printing company developing 3D-printed drug formulations and working with regulators (including FDA IND clearances). It is the most comparable direct competitor to FabRx in pharmaceutical 3D printing hardware and formulation services.
- Aprecia Pharmaceuticals: Aprecia is the pioneer of pharmaceutical 3D printing, holding the first FDA-approved 3D-printed drug (Spritam). Its ZipDose platform competes directly with FabRx's M3DIMAKER in producing personalized oral dosage forms for hospitals and pharmacies.
- MB Therapeutics (formerly DiHeSys): MB Therapeutics is a German pharmaceutical 3D printing startup focused on personalized medicine and printing of individualized dosage forms. It is a direct European competitor in pharmaceutical 3D printing technology.
- Laxxon Medical: Laxxon Medical develops 3D-printed pharmaceuticals with its SPID-Technology platform, focused on oral drug delivery and personalized dosing. Comparable to FabRx in target market (personalized oral dosage forms) and technology category.
Emerging players
- Inventia Healthcare: Inventia develops powder-based pharmaceutical 3D printing technology for personalized medicine and clinical/research applications. Comparable as an emerging specialist in pharma 3D printing but with narrower scope than FabRx's multi-technology platform.
Broad incumbents
- Catalent: Catalent is a major CDMO with capabilities in oral solid dose manufacturing and is exploring advanced drug delivery technologies. As a broad incumbent in pharma manufacturing services, it represents the consolidation target or large competitor FabRx may eventually compete against for hospital compounding contracts.
- GEA Pharma & Healthcare: GEA supplies industrial processing equipment for pharmaceutical manufacturing, including equipment for solid dosage forms. As an industrial incumbent in pharma manufacturing equipment, it could enter the personalized 3D printing space and compete with FabRx for hospital pharmacy installations.
- Glatt Group: Glatt offers integrated solutions for pharmaceutical production including solid dosage form manufacturing equipment. It is comparable to FabRx as a provider of equipment used in pharmaceutical production, though with a much broader and more established industrial equipment portfolio.
- Thermo Fisher Scientific (Patheon/CDMO): Through its Patheon CDMO business, Thermo Fisher offers pharmaceutical development and manufacturing services including oral solid dose capabilities. As a broad incumbent in pharma services, it competes for hospital and CDMO contracts that FabRx's platform could also address.
Others
- Evonik Industries: Evonik is a global specialty chemicals company and supplier of pharmaceutical excipients, including materials used in 3D-printed drug formulations. It is a partner of FabRx (excipient supplier) and thematically adjacent as the materials backbone of pharmaceutical 3D printing ecosystems.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
FabRx social profiles
Digital presenceFabRx compliance and trust
Trust signalCompliance1 record
FabRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
FabRx leadership team
Management profileNumber of profiles
Profiles11 records
FabRx subsidiaries and ownership
Company hierarchySubsidiaries2 records
FabRx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FabRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FabRx
What does FabRx do?
FabRx develops and commercializes the M3DIMAKER ecosystem of GMP-compliant pharmaceutical 3D printers (single-printhead M3DIMAKER 1 and multi-printhead M3DIMAKER 2), control software, in-line quality control sensors, and Pharma-ink formulation services that enable pharmacies, hospitals, and pharmaceutical companies to produce personalized medicines and small-batch pharmaceuticals on-site. The platform supports multiple manufacturing modalities including 3D printing, blister filling, capsule filling, and suppository filling under a single integrated system.
Is FabRx a public or private company?
FabRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was FabRx founded?
FabRx was founded in 2014. It employs 11 to 50 people.
Where is FabRx based?
FabRx is headquartered in Ashford, United Kingdom, in the Europe region.
How does FabRx make money?
Four revenue lines are on record. Pharmaceutical 3D Printer Sales are the primary driver. The others are printer Subscription, software Licensing and pharma-ink Development Services.
Who are FabRx's main competitors?
Direct peers on record are Triastek, Aprecia Pharmaceuticals, MB Therapeutics (formerly DiHeSys) and Laxxon Medical. Inventia Healthcare is listed as an emerging player. Broad incumbents are Catalent, GEA Pharma & Healthcare, Glatt Group and Thermo Fisher Scientific (Patheon/CDMO). Evonik Industries is listed as an others.
Does FabRx have an API?
No public API is recorded for FabRx.
What industry is FabRx in?
FabRx's product category is Pharmaceutical 3D Printing Systems. Its primary akta.pro industry code is HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 3231 and its SIC code is 3555.